↓ Skip to main content

Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court’s Recent Rulings do not Solve Fundamental Barriers to Competition

Overview of attention for article published in Drugs, November 2018
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news
4 news outlets
blogs
1 blog
twitter
5 X users

Citations

dimensions_citation
42 Dimensions

Readers on

mendeley
80 Mendeley